Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services
Rhea-AI Summary
Wellgistics Health (NASDAQ:WGRX) announced a pilot collaboration with Kare PharmTech and Kare Clinicals to integrate its MSO infrastructure for chronic care management (CCM) and remote patient monitoring (RPM) across multiple provider offices.
The U.S. RPM market is cited at $14 billion, projected to reach ~$29 billion by 2030 at a 12.6% CAGR. The pilot has generated 1,500+ claims to date and is intended as a base for broader provider expansion. Wellgistics plans to leverage its network of 6,500+ independent pharmacies to help identify eligible patients and support engagement, while participating pharmacists may gain access to new clinical service revenue opportunities.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – WGRX
On the day this news was published, WGRX gained 23.10%, reflecting a significant positive market reaction. Argus tracked a peak move of +80.0% during that session. Argus tracked a trough of -4.0% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $12.29M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
WGRX was down 14.44% with mixed peers: PETS (-2.2%), HITI (-2.41%), HKPD (-6.67%), SCNX (-2.71%), while SSY gained 9.31%, pointing to stock-specific pressure rather than a clean sector move.
Previous Partnership Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 14 | Kare JV partnership | Positive | +20.1% | Definitive joint venture with Kare PharmTech’s Kare Rx Hub to expand access. |
| Feb 09 | NFL Alumni deal | Positive | -1.6% | Partnership with NFL Alumni Health to deploy EinsteinRx and PharmacyChain. |
| Jun 25 | Platform expansion | Positive | -8.9% | Reported Q2 growth with 116 manufacturer partnerships and 12,400+ new products. |
Partnership headlines have produced mixed reactions, with one strong gain and two notable declines, indicating no consistent upside pattern for similar announcements.
Over the past year, Wellgistics has repeatedly used partnerships to expand its platform. Key deals include the April 14, 2026 joint venture with Kare PharmTech, which led to a 20.08% gain, the February 9, 2026 collaboration with NFL Alumni Health, and the June 25, 2025 update highlighting 116 new manufacturer partnerships and 12,400+ new products. Today’s CCM/RPM MSO pilot continues this partnership-led strategy but comes as the stock trades near its 52-week low and below its 200-day moving average.
Historical Comparison
In the past, WGRX partnership news averaged a 3.2% move, with outcomes ranging from -8.91% to +20.08%. Today’s -14.44% reaction to another Kare-linked collaboration is a weaker response than typical.
Partnerships show a progression from broad platform and pharmacy network growth in 2025 to higher-profile collaborations in 2026, including NFL Alumni Health and the Kare PharmTech joint venture, with the new CCM/RPM MSO pilot deepening the Kare relationship.
Regulatory & Risk Context
An effective S-3 shelf filed on April 15, 2026 allows Wellgistics to offer up to $200,000,000 of various securities for general corporate purposes. As of the latest data, usage_count is 0, indicating capacity remains available through the April 15, 2029 expiration.
Market Pulse Summary
The stock surged +23.1% in the session following this news. A strong positive reaction aligns with management’s ongoing shift toward tech-enabled, patient-centric services and recurring clinical programs. Prior partnership news produced an average move of 3.2%, with one Kare JV headline generating 20.08%. Investors would still need to weigh balance-sheet pressure from obligations like the Marco Capital forbearance agreement and the large $200,000,000 shelf, which could enable future equity issuance.
Key Terms
chronic care management medical
remote patient monitoring medical
cagr financial
AI-generated analysis. Not financial advice.
Highlights:
According to third-party industry reports, the U.S. RPM market is currently
$14 Billion alone and expected to reach approximately$29 Billion by 2030, representing a12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models¹Pilot initiative launched across multiple provider offices focused on chronic care management (CCM) and remote patient monitoring (RPM) through it's MSO infrastructure
Approximately 1,500+ claims generated to date through the pilot infrastructure with expansion roadmap targeting additional providers
Wellgistics Pharmacy Network of 6,500+ independent pharmacies positioned to support patient engagement and care coordination initiatives
Participating pharmacists expected to gain access to new clinical service revenue opportunities
TAMPA, FL / ACCESS Newswire / May 13, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced a pilot collaboration with Kare PharmTech and Kare Clinicals integrating its MSO infrastructure to support chronic care management ("CCM") and remote patient monitoring ("RPM") services across participating provider offices. According to third-party industry reports, the U.S. RPM market is currently
The pilot program currently includes multiple provider offices, with Kare Clinicals MSO serving as the billing provider on behalf of participating offices and rendering providers. The initiative is designed to support patient engagement, care coordination, and longitudinal monitoring programs through scalable operational and technology-enabled workflows. All CCM and RPM services are expected to be furnished and billed by appropriately licensed providers and participating entities in accordance with applicable federal and state healthcare laws, reimbursement requirements, and payor program rules.
The companies stated that the pilot infrastructure has already generated 1,500+ claims and is intended to serve as the foundation for broader expansion efforts targeting approximately additional providers over time. As part of the collaboration, Wellgistics Health intends to leverage its network of more than 6,500 independent pharmacies to help identify and support eligible patients who may benefit from CCM and RPM services. Participating pharmacies within the Wellgistics Pharmacy Network may also have opportunities to participate in clinical engagement initiatives associated with the program.
Prashant Patel, President and CEO of Wellgistics Health, Inc., stated, "We believe the convergence of pharmacy engagement, provider connectivity, and technology-enabled care coordination represents a significant opportunity to improve patient outcomes while creating new economic opportunities for independent pharmacies. Through this pilot collaboration with Kare PharmTech, we are establishing infrastructure designed to support scalable patient engagement models across chronic care management and remote patient monitoring programs."
Mital Panera, Founder and Chief Executive Officer of Kare PharmTech, added, "Our focus has been on building an operationally efficient MSO platform capable of supporting providers with care coordination and reimbursement workflows. By collaborating with Wellgistics Health and its pharmacy network, we believe we can further expand patient participation, improve continuity of care, and create a scalable framework for future provider growth."
The companies noted that the pilot program remains subject to ongoing operational development, provider participation, and regulatory compliance considerations as expansion efforts continue.
About Wellgistics Health, Inc.
Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.
About Kare PharmTech, LLC
Kare Clinicals is part of the larger ecosystem of companies owned by Kare PharmTech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's expectations, beliefs, plans, objectives, intentions, strategies, future events, or performance, including statements regarding the potential benefits, scalability, expansion, commercialization, provider participation, reimbursement opportunities, patient engagement initiatives, operational capabilities, and future development of the pilot collaboration with Kare PharmTech and Kare Clinicals, as well as the anticipated role of the Wellgistics Pharmacy Network in supporting CCM and RPM initiatives. Words such as "anticipate," "believe," "could," "expect," "intend," "may," "plan," "potential," "project," "seek," "should," "will," and similar expressions are intended to identify forward-looking statements.
These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation, risks relating to provider adoption and participation, reimbursement outcomes, patient engagement levels, operational execution, scalability of the pilot program, regulatory and healthcare compliance considerations, changes in applicable laws or reimbursement policies, market acceptance of the Company's services, competitive factors, and the Company's ability to develop and maintain strategic relationships and successfully implement its business strategy.
The pilot collaboration described in this press release is exploratory in nature, and there can be no assurance that the initiative will result in expanded commercial relationships, material revenue opportunities, or long-term operational success.
Additional information regarding these and other risks can be found in the Company's filings with the U.S. Securities and Exchange Commission, including the risk factors contained therein. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.com
1 MarketsandMarkets - U.S. Remote Patient Monitoring Market Report
SOURCE: Wellgistics Health, Inc.
View the original press release on ACCESS Newswire